THE PROGNOSIS OF THE POSSIBLE FETAL AND PLACENTAL COMPLICATIONS DURING DELIVERY BY MEASURING MATERNAL SERUM LEVELS OF PREGNANCY-SPECIFIC BETA-1-GLYCOPROTEIN (SP1)
THE PROGNOSIS OF THE POSSIBLE FETAL AND PLACENTAL COMPLICATIONS DURING DELIVERY BY MEASURING MATERNAL SERUM LEVELS OF PREGNANCY-SPECIFIC BETA-1-GLYCOPROTEIN (SP1)
复制标题
DOI：
10.1007/bf02110026
复制
发表时间：
1981-01-01
期刊：
影响因子：
--
通讯作者：
SZABO, DG
中科院分区：
文献类型：
--
作者：
KARG, NJ;CSABA, IF;SZABO, DG
病理性母体SP1 [妊娠特异性β- 1-糖蛋白]血清水平和分娩期间可能的胎儿并发症进行了研究。1954年，对823例妊娠32 ~ 40周的孕妇进行了SP1测定。基于SP1血清浓度，形成患者组。病理性SP1血清浓度通常与胎儿宫内发育迟缓、宫内窘迫和剖宫产相关。SP1胎盘功能试验是一种简便、价廉的筛查胎盘功能不全的方法。
The correlation between pathological maternal SP1 [pregnancy specific .beta.-1-glycoprotein] serum levels and possible fetal complications during delivery was studied. In 1954, SP1 measurements were made in 823 pregnant women between the 32nd-40th gestational wk. Based on SP1 serum concentrations, groups of patients were formed. Pathological SP1 serum concentrations are frequently associated with intrauterine growth retardation, imminent intrauterine asphyxia and cesarean section indicated by fetal distress. SP1 placental function test is recommended as a simple, inexpensive screening method for the detection of placental insufficiency.